| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
SUPPLEMENT |
From the Sydney Melanoma Unit and the Melanoma and Skin Cancer Research Institute (JFT, JRS, RFU, VSK, RAS) and Department of Anatomical Pathology (RAS), Royal Prince Alfred Hospital; and Departments of Surgery (JFT, JRS) and Medicine (RFU), The University of Sydney, Sydney, New South Wales, Australia.
Correspondence: Address correspondence and reprint requests to: J. F. Thompson, MD, Sydney Melanoma Unit, Royal Prince Alfred Hospital, Camperdown, New South Wales 2050, Australia; Fax: 61-2-9550-6316; E-mail: thompson{at}smu.org.au
ABSTRACT
The sentinel node (SN) concept is not new, but its potential surgical application was not fully appreciated until the landmark report by Morton and Cochran et al. in 1992. It has since been confirmed that SN status in melanoma patients accurately reflects the status of the entire regional node field, and is a critically important prognostic indicator. However, randomized trials have yet to determine whether the SN biopsy technique is of any therapeutic value. With extended follow-up times, false-negative SN rates of up to 15% are being reported and presumably represent failures of nuclear medicine and/or surgery and/or histopathology. Innovative methods of increasing the accuracy of SN identification and of checking this retrospectively are being assessed. The next great challenge is to develop methods of SN assessment that are noninvasive yet are even more accurate than present methods. Techniques such as in vivo proton magnetic resonance spectroscopy hold great promise and suggest that this goal might be achievable.
Key Words: History • Lymphatic mapping • Melanoma • Sentinel node
This article has been cited by other articles:
 |
|
 |
|
  C. R. Rossi, G. L. De Salvo, E. Bonandini, S. Mocellin, M. Foletto, S. Pasquali, P. Pilati, M. Lise, D. Nitti, E. Rizzo, et al. Factors Predictive of Nonsentinel Lymph Node Involvement and Clinical Outcome in Melanoma Patients With Metastatic Sentinel Lymph Node Ann. Surg. Oncol., April 1, 2008; 15(4): 1202 - 1210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mocellin, D. S.B. Hoon, P. Pilati, C. R. Rossi, and D. Nitti Sentinel Lymph Node Molecular Ultrastaging in Patients With Melanoma: A Systematic Review and Meta-Analysis of Prognosis J. Clin. Oncol., April 20, 2007; 25(12): 1588 - 1595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Govindarajan, D. M. Ghazarian, D. R. McCready, and W. L. Leong Histological Features of Melanoma Sentinel Lymph Node Metastases Associated with Status of the Completion Lymphadenectomy and Rate of Subsequent Relapse Ann. Surg. Oncol., February 1, 2007; 14(2): 906 - 912. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Shayan, M. G. Achen, and S. A. Stacker Lymphatic vessels in cancer metastasis: bridging the gaps Carcinogenesis, September 1, 2006; 27(9): 1729 - 1738. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mocellin, A. Ambrosi, M. C. Montesco, M. Foletto, G. Zavagno, D. Nitti, M. Lise, and C. R. Rossi Support Vector Machine Learning Model for the Prediction of Sentinel Node Status in Patients With Cutaneous Melanoma Ann. Surg. Oncol., August 1, 2006; 13(8): 1113 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Rossi, G. L. De Salvo, G. Trifiro, S. Mocellin, G. Landi, G. Macripo, P. Carcoforo, G. Ricotti, G. Giudice, F. Picciotto, et al. The Impact of Lymphoscintigraphy Technique on the Outcome of Sentinel Node Biopsy in 1,313 Patients with Cutaneous Melanoma: An Italian Multicentric Study (SOLISM-IMI) J. Nucl. Med., February 1, 2006; 47(2): 234 - 241. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
